Immunoglobulin G4, Anti-(Human Lysyl Oxidase Homolog 2) (Human-Mus Musculus Monoclonal Gs-6624 Heavy Chain), Disulfide With Human-Mus Musculus Monoclonal Gs-6624 .Kappa.-Chain, Dimer
Hepatitis C Virus Infection
Explore 12 assets in Hepatitis C Virus Infection →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Gilead Sciences
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01707472CT.gov Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4, Anti-(Human Lysyl Oxidase Homolog 2) (Human-Mus Musculus Monoclonal Gs-6624 Heavy Chain), Disulfide With Human-Mus Musculus Monoclonal Gs-6624 .Kappa.-Chain, Dimer (this asset) | Gilead Sciences | P2 | CCC · 50 |
| Veruprevir | AbbVie | P4 | A |
| Daclatasvir | MTI University | P4 | A |
| Pibrentasvir | AbbVie | P3 | A |
| Glecaprevir | AbbVie | P3 | A |
| Velpatasvir | Peking University People's Hospital | P4 | A |
| Dasabuvir | AbbVie | P3 | A |
| Ombitasvir | AbbVie | P3 | A |
| Ribavirin | Peking University People's Hospital | P4 | A |
+42 more in the Hepatitis C Virus Infection cohort
Other indications for Immunoglobulin G4, Anti-(Human Lysyl Oxidase Homolog 2) (Human-Mus Musculus Monoclonal Gs-6624 Heavy Chain), Disulfide With Human-Mus Musculus Monoclonal Gs-6624 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fibrotic Liver Disease | — | P2 | CCC · 53 |
| HIV Infectious Disease | — | P2 | CCC · 50 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4, Anti-(Human Lysyl Oxidase Homolog 2) (Human-Mus Musculus Monoclonal Gs-6624 Heavy Chain), Disulfide With Human-Mus Musculus Monoclonal Gs-6624 .Kappa.-Chain, Dimer in Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-lysyl-oxidase-homolog-2-human-mus-musculus-monoclonal-gs-6624-heavy-chain-disulfide-with-human-mus-musculus-monoclonal-gs-6624-kappa-chain-dimer-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →